Targeted trial for black Women's cancer halted after just 4 patients
NCT ID NCT05263492
Summary
This study tested whether combining two existing cancer drugs (lenvatinib and pembrolizumab) could help control recurrent endometrial cancer specifically in Black patients. The trial was designed to address a lack of data in this population but was terminated early after enrolling only 4 participants. Researchers aimed to see if the drug combination could shrink tumors and delay cancer progression in this understudied group.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Virginia Commonwealth University
Richmond, Virginia, 23298, United States
Conditions
Explore the condition pages connected to this study.